Orelabrutinib is a drug for the treatment of cancer. In China, it is approved for patients with mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma, who have received at least one treatment in the past. From Wikipedia
Existing cancer approvals in China and Singapore offer clinical precedent for Zenas’ autoimmune push.
